TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer

NCT00102973 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

244

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Neoplasms

Interventions

DRUG: TLK286 in Combination with Carboplatin
DRUG: Doxorubicin HCl Liposome Injection

Sponsor

Telik